Create an Account
  1. Home
  2. Specialty
  3. General Ophthalmology

Earlier Co-Management of Today’s Glaucoma Patient With the Latest Medical Therapies, Drug-Delivery Methods, and MIGS Technologies

ReachMD Healthcare Image
Media formats available:
Details
Presenters

  • Overview

    Learn the latest advances in medical therapies and drug-delivery methods aimed to improve patient compliance and prevent vison loss. Faculty will discuss the latest MIGS technologies and the ideal timing of surgical interventions. Learn how to educate, set expectations, and co-manage today’s glaucoma patients.


    Agenda: (all times CT)

    6:00 PM     In-Person Dinner Registration Reception
    6:30-6:40 PM     Introduction
    6:40-6:50 PM     Best Practices and Unmet Needs in Glaucoma Screening
    6:50-6:55 PM     Panel Discussion
    6:55-7:05 PM     Current and Emerging Medical Therapies to Improve Patient Compliance and Prevent Vision Loss
    7:05-7:10 PM     Panel Discussion
    7:10-7:20 PM     Novel Drug-Delivery Methods, Sustained-Release Devices, and the Latest MIGS Technologies
    7:20-7:25 PM     Panel Discussion
    7:25-7:35 PM     The Glaucoma Patient Journey: How to Educate, Set Expectations, and Co-Manage Patients
    7:35-7:40 PM     Panel Discussion
    7:40-7:45 PM     Summary and Conclusions

     

    This activity is supported by unrestricted educational grants from Alcon and Sight Sciences.

     

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Review unmet needs of modern glaucoma patients, including the impact of patient compliance with medical therapy on glaucoma progression, and identify the importance of earlier intervention with the glaucoma patient, regardless of disease severity levels

    • Compare and contrast current and emerging medical therapies, drug-delivery methods, and MIGS treatment options for glaucoma with the goal of improving patient compliance and preventing vison loss
    • Understand the glaucoma patient journey: How to identify the ideal patients with glaucoma and educate, set expectations, and co-manage them

    • Accreditation

      Evolve Medical Education LLC (Evolve) is a COPE-accredited administrator.


      This in-person symposium, COPE Activity Number 124058, is accredited by COPE for continuing education for optometrists for 1.25 hours.
      Course #: 78706-GL
      Activity #: 124058


      This virtual interactive symposium, COPE Activity Number 124060, is accredited by COPE for continuing education for optometrists for 1.25 hours.
      Course #: 78707-GL
      Activity #: 124060
       
      COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.

       

    • Participation Method

      In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

      Course Viewing Requirements

      Supported Browsers:
      Internet Explorer 11 for Windows
      Edge (recent versions; Chromium-based) for Windows
      Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
      Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
      Safari (recent versions) for Mac OSX, or iOS

      Hardware Requirements:
      4GB+ RAM
      Recommended internet speed 5Mbps+

    • Faculty and Disclosures

      Cecelia C. Koetting, OD, FAAO, Dipl ABO

      Cecelia C. Koetting, OD, FAAO, Dipl ABO

      Hines Sight
      Denver, CO


      Thomas M. Chester, OD, FAAO

      Thomas M. Chester, OD, FAAO

      Clinical Director
      Cleveland Eye Clinic
      Brecksville, OH


      Ahmad M. Fahmy, OD, FAAO, Dipl ABO

      Ahmad M. Fahmy, OD, FAAO, Dipl ABO

      Director of Optometric Services

      Minnesota Eye Consultants

      Bloomington, MN


      Leslie O’Dell, OD, FAAO

      Leslie O’Dell, OD, FAAO

      Medical Director 
      Director of Clinical Research 
      Medical Optometry America 
      York, PA 


      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

      The following faculty/staff members have the following financial relationships with ineligible companies.

      Cecelia C. Koetting, OD, FAAO, Dipl ABO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Aldeyra, Allergan, Avellino, Bruder, Dompé, Eyevance, Glaukos, Kala Pharmaceuticals, Orasis, OysterPoint, RVL, and Thea. Grant/Research Support: Johnson & Johnson Vision. Speaker's Bureau: Alcon, Dompé, Eyevance, OysterPoint, and RVL.

      Thomas M. Chester, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Allergan, Dompé, Kala Pharmaceuticals, Novartis, Oyster Point Pharma, and Sight Sciences. Grant/Research Support: Ocular Therapeutix and Sight Sciences. Speaker's Bureau: Sight Sciences. Stock/Shareholder: Sight Sciences.

      Ahmad M. Fahmy, OD, FAAO, Dipl ABO, has had a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Allergan, Kala Pharmaceuticals, and Sun Pharmaceutical Industries. Speaker's Bureau: Allergan, BioTissue, NuSight Medical, and Sight Sciences.

      Leslie O’Dell, OD, FAAO, has had a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Alcon, Alderya, Allergan, Bausch + Lomb, EyeDetech, Eye Eco, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, Ocuphire, Oyster Point, Sight Sciences, Sun Pharmaceutical Industries, and Tarsus Pharmaceuticals. Speaker's Bureau: Aerie Pharmaceuticals, Alcon, Allergan/AbbVie, Bausch + Lomb, Kala Pharmaceuticals, Oyster Point Pharma, and Sun Pharmaceutical Industries. Stock/Shareholder: Eyes are the Story, EyeDetech, and Medical Optometry America.

      The Evolve and The Fundingsland Group staff, planners, and reviewers have no financial relationships with ineligible companies.

       

    • Disclaimer

      OFF-LABEL STATEMENT
      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      DISCLAIMER
      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group, Alcon, or Sight Sciences. 

       

    • System Requirements

      • Supported Browsers (2 most recent versions):
        • Google Chrome for Windows, Mac OS, iOS, and Android
        • Apple Safari for Mac OS and iOS
        • Mozilla Firefox for Windows, Mac OS, iOS, and Android
        • Microsoft Edge for Windows
      • Recommended Internet Speed: 5Mbps+

    • Publication Dates

      Release Date:

      Expiration Date:

    Ready to Claim Your Credits?

    You have attempts to pass this post-test. Take your time and review carefully before submitting.

    Good luck!

    LIVE ON REACHMD RADIOBack to live radio
    ReachMD Radio

    Loading...

    00:00
    00:00
      Register

      We're glad to see you're enjoying Evolve Medical Education…
      but how about a more personalized experience?

      Register for free